Changes to COVID-19 vaccine access, announced Tuesday by the Food and Drug Administration, find the agency shifting away from a broad vaccination approach.

The departure from the prior standard instead gives access to updated versions of the vaccine to those 65 and older or with a health condition, and requires vaccine manufacturers to conduct additional clinical trials on their products. The announcement was published in the New England Journal of Medicine.

The news concerned some vaccine experts, who worry it will endanger the population and leave out people who may be protecting immunocompromised or sick loved ones.

While SARS-CoV-2 cases and hospitalizations are much lower now than during the acute phase of the pandemic, hundreds of people still die from COVID-19 each week, per the

See Full Page